Related Experiment Video
Updated: May 27, 2025

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
MIRA: Myocardial insulin resistance app for clinical practice
Queralt Martín-Saladich1, Rafael Simó2, José Raul Herance3
1Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute (VHIR), Nuclear Medicine, Radiology and Cardiology Departments, Vall d'Hebron University Hospital, Autonomous University Barcelona, Barcelona 08035, Spain; BCN Medtech, Department of Engineering, Universitat Pompeu Fabra, Barcelona 08018, Spain.
Background And Objective:
Type 2 diabetes (T2D) is a prevalent disease characterized by insulin resistance (IR), leading to energy disruptions in myocardial cells and increasing cardiovascular (CV) risk. Current diagnostic methods are either systemic, thus lacking tissue-specific information, or invasive. The hyperinsulinemic euglycemic clamp (HEC) combined with [18F]FDG-PET images, only used in clinical trials, allow to assess regional IR and identify phenotypes within T2D, linking myocardial IR to higher CV risk. However, phenotyping is not easily accessible, creating a need for alternative assessment tools. Thus, we propose a myocardial IR model to address these gaps and improve T2D management.
Methods:
The study included forty-two patients with T2D who enrolled in a clinical trial (NCT02248311) and who underwent biochemical analyses, anthropometric measurements and [18F]FDG PET/CT imaging before and after HEC with. Patients were phenotyped into mIR and mIS according to poor or good uptake after HEC, respectively. The proposed predictive model was based on stepwise regression including feature selection to provide an estimate of myocardial IS and thus IR=1/IS by using biochemical parameters in T2D. A software application, the myocardial IR app (MIRA), was developed using MATLAB.
Results:
MIRA was developed as a myocardial IR estimator (R2=0.97, p=7.1 × 10-7, error=1.24) for patients with T2D. Moreover, since HEC is not allowed in rutinary clinical practice, the application includes a prediction of the expected myocardial HEC [18F]FDG uptake from baseline uptake (r=0.52, p=5 × 10-4, R2=0.60). The app also yields the patient's phenotype, either mIR or mIS, according to poor or good uptake after HEC. Enhanced CV risk exposure due to altered T2D biomarkers and associated to mIR is also provided with highlighted features.
Conclusions:
We hereby present MIRA, a myocardial IR calculation app to manage myocardial-specific affectation in T2D, as well as to provide with patient phenotyping and CV risk assessment.
More Related Videos
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: The Receptor and Signaling Pathways
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...